Abstract
There is wide interpatient variability in drug response and toxicity to standard doses of most anticancer medications. Genetic polymorphisms in genes encoding metabolic enzymes, receptors and drug transporters targeted by anticancer medications are often found, in part, to be responsible for the observed variability. Approximately 80% of all sequence variations residing in genes is in the form of single nucleotide polymorphisms or SNPs. The location of SNPs can be in the protein coding sequence, regulatory regions or at exon-intron boundaries of genes. Adverse drug reactions resulting from these sequence variations are due to changes in the activity of the encoded protein (in many instances the protein is non-functional) or perturbations in the level of gene expression. The goal of pharmacogenetic testing is to identify genetic polymorphisms that predispose patients to an adverse drug reaction, thereby allowing the health care provider to make informed decisions pertaining to the type of drug, dosage and dosage scheduling to be administered.
Keywords: Pharmacogenetics, single nucleotide polymorphisms, genetic variation, thiopurine S-methyltransferase, thymidylate synthase, dihydropyrimidine dehydrogenase, ATP-binding cassette transporters, multidrug resistance-associated protein, cancer health disparities.
Anti-Cancer Agents in Medicinal Chemistry
Title: Pharmacogenetics of Drug Metabolizing Enzymes and Transporters: Effects on Pharmacokinetics and Pharmacodynamics of Anticancer Agents
Volume: 10 Issue: 8
Author(s): Norman H. Lee
Affiliation:
Keywords: Pharmacogenetics, single nucleotide polymorphisms, genetic variation, thiopurine S-methyltransferase, thymidylate synthase, dihydropyrimidine dehydrogenase, ATP-binding cassette transporters, multidrug resistance-associated protein, cancer health disparities.
Abstract: There is wide interpatient variability in drug response and toxicity to standard doses of most anticancer medications. Genetic polymorphisms in genes encoding metabolic enzymes, receptors and drug transporters targeted by anticancer medications are often found, in part, to be responsible for the observed variability. Approximately 80% of all sequence variations residing in genes is in the form of single nucleotide polymorphisms or SNPs. The location of SNPs can be in the protein coding sequence, regulatory regions or at exon-intron boundaries of genes. Adverse drug reactions resulting from these sequence variations are due to changes in the activity of the encoded protein (in many instances the protein is non-functional) or perturbations in the level of gene expression. The goal of pharmacogenetic testing is to identify genetic polymorphisms that predispose patients to an adverse drug reaction, thereby allowing the health care provider to make informed decisions pertaining to the type of drug, dosage and dosage scheduling to be administered.
Export Options
About this article
Cite this article as:
H. Lee Norman, Pharmacogenetics of Drug Metabolizing Enzymes and Transporters: Effects on Pharmacokinetics and Pharmacodynamics of Anticancer Agents, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (8) . https://dx.doi.org/10.2174/187152010794474019
DOI https://dx.doi.org/10.2174/187152010794474019 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Vaccines Explored in Patients with Non-Small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Status of Bi- and Multi-Nuclear Platinum Anticancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Down Regulation of Differentiated Embryo-Chondrocyte Expressed Gene 1 is Related to the Decrease of Osteogenic Capacity
Current Drug Targets γ-AApeptides as a New Strategy for Therapeutic Development
Current Medicinal Chemistry Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Synthesis and Biological Evaluation of a Novel Apogossypolone Derivative
Letters in Drug Design & Discovery Current Development of Pd(II) Complexes as Potential Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Post-Translational Modification of Transcription Factors: Mechanisms and Potential Therapeutic Interventions
Current Molecular Pharmacology Editorial [Hot Topic: The Plasminogen Activation System in Pathology: Use in Prognosis and Therapy (Guest Editor: Marie Ranson)]
Current Drug Targets Mechanisms of Resistance to Photodynamic Therapy
Current Medicinal Chemistry Recent Advances in the Structure-Based and Ligand-Based Design of IKKβ Inhibitors as Anti-inflammation and Anti-cancer Agents
Current Medicinal Chemistry Effects of a Series of Acidic Drugs on L-Lactic Acid Transport by the Monocarboxylate Transporters MCT1 and MCT4
Current Pharmaceutical Biotechnology Effect of Non-Steroidal Anti-Inflammatory Drugs on Bone Turnover: An Evidence-Based Review
Reviews on Recent Clinical Trials Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design FOXM1 and its Oncogenic Signaling in Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Selenium Deficiency in Soils and Crops and its Impact on Animal and Human Health
Current Nutrition & Food Science On the Nature of the Tumor-Initiating Cell
Current Stem Cell Research & Therapy Targeting of Jak/STAT Pathway in Antigen Presenting Cells in Cancer
Current Cancer Drug Targets Nanoradiopharmaceuticals for Nanomedicine: Building the Future
Recent Patents on Nanomedicine